Intravesical bacillus Calmette-Guerin therapy:: experience with a reduced dwell-time in patients with pronounced side-effects

被引:28
作者
Andius, P [1 ]
Fehrling, M [1 ]
Holmäng, S [1 ]
机构
[1] Sahlgrenska Univ Hosp, Dept Urol, S-41345 Gothenburg, Sweden
关键词
bladder neoplasm; carcinoma in situ; bacille Calmette-Guerin; optimum dose;
D O I
10.1111/j.1464-410X.2005.05817.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To report the side-effects after a reduction in the dwell-time in patients who had pronounced symptoms after intravesical bacillus Calmette-Guerin (BCG) treatment, as side-effects such as fever, haematuria, and frequency are common and sometimes severe after BCG treatment in patients with bladder cancer. PATIENTS AND METHODS The dwell-time was reduced to <= 30 min in 51 patients who had pronounced side-effects after the preceding BCG instillation. All patients self-reported side-effects after each instillation in a questionnaire. RESULTS After reducing the BCG dwell-time, fever, chills, dysuria and the overall time-to-recovery were significantly reduced but frequency and haematuria were not influenced. Patients with carcinoma in situ had significantly less dysuria than patients with papillary tumours. There was no difference in the treatment results between patients who had a normal dwell-time and a reduced dwell-time, determined at the first and second follow-up cystoscopy. CONCLUSION Reducing the BCG dwell-time to <= 30 min could be an alternative to a dose reduction in patients who experience pronounced side-effects after BCG instillations. The long-term outcome after reducing dwell-time and after dose reduction has not been studied and warrants further investigation.
引用
收藏
页码:1290 / 1293
页数:4
相关论文
共 16 条
  • [1] Modified induction course: A solution to side-effects?
    Bassi, P
    Spinadin, R
    Carando, R
    Balta, G
    Pagano, F
    [J]. EUROPEAN UROLOGY, 2000, 37 : 31 - 32
  • [2] Berry D L, 1996, Int J Urol, V3, P98, DOI 10.1111/j.1442-2042.1996.tb00490.x
  • [3] The quality of life during intravesical bacillus Calmette-Guerin therapy
    Bohle, A
    Balck, F
    vonWietersheim, J
    Jocham, D
    [J]. JOURNAL OF UROLOGY, 1996, 155 (04) : 1221 - 1226
  • [4] Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance
    Griffiths, TRL
    Charlton, M
    Neal, DE
    Powell, PH
    [J]. JOURNAL OF UROLOGY, 2002, 167 (06) : 2408 - 2412
  • [5] CHOICE OF AN OPTIMAL DILUENT FOR INTRAVESICAL BACILLUS CALMETTE-GUERIN ADMINISTRATION
    HUDSON, MA
    CATALONA, WJ
    RITCHEY, JK
    ASLANZADEH, J
    BROWN, EJ
    RATLIFF, TL
    [J]. JOURNAL OF UROLOGY, 1989, 142 (06) : 1438 - 1441
  • [6] IMMUNOTHERAPY OF MURINE TRANSITIONAL CELL-CARCINOMA
    LAMM, DL
    REICHERT, DF
    HARRIS, SC
    LUCIO, RM
    [J]. JOURNAL OF UROLOGY, 1982, 128 (05) : 1104 - 1108
  • [7] Superficial bladder cancer
    Lamm D.L.
    [J]. Current Treatment Options in Oncology, 2002, 3 (5) : 403 - 411
  • [8] Beware the BCG failures: A review of one institution's results
    Lockyer, CRW
    Sedgwick, JEC
    Gillatt, DA
    [J]. EUROPEAN UROLOGY, 2002, 42 (06) : 542 - 546
  • [9] Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer
    Martínez-Piñeiro, JA
    Flores, N
    Isorna, S
    Solsona, E
    Sebastián, JL
    Pertusa, C
    Rioja, LA
    Martínez-Piñeiro, L
    Vela, R
    Camacho, JE
    Nogueira, JL
    Pereira, I
    Resel, L
    Muntañola, P
    Galvis, F
    Chesa, N
    De Torres, JA
    Carballido, J
    Bernuy, C
    Arribas, S
    Madero, R
    [J]. BJU INTERNATIONAL, 2002, 89 (07) : 671 - 680
  • [10] INTRACAVITARY BACILLUS CALMETTE-GUERIN IN TREATMENT OF SUPERFICIAL BLADDER TUMORS
    MORALES, A
    EIDINGER, D
    BRUCE, AW
    [J]. JOURNAL OF UROLOGY, 1976, 116 (02) : 180 - 183